This is newsworthy because I expect trials like this to fail in GBM, and I'm very biased against single agent kinase inhibitor trials for GBM, but this one showed regorafenib to actually be superior to lomustine in a randomized phase 2 trial.
 |
Showing posts with label regorafenib. Show all posts
Showing posts with label regorafenib. Show all posts
Saturday, 15 December 2018
Regorafenib superior to lomustine in randomized phase 2 trial for reGBM
http://sci-hub.tw/10.1016/S1470-2045(18)30675-2
This is newsworthy because I expect trials like this to fail in GBM, and I'm very biased against single agent kinase inhibitor trials for GBM, but this one showed regorafenib to actually be superior to lomustine in a randomized phase 2 trial.
This is newsworthy because I expect trials like this to fail in GBM, and I'm very biased against single agent kinase inhibitor trials for GBM, but this one showed regorafenib to actually be superior to lomustine in a randomized phase 2 trial.
Subscribe to:
Posts (Atom)